Aflac Incorporated Q2 2026 Earnings Recap

Aflac’s shares fell 1.6% post-earnings as investors digested a deceleration in Japan sales against a strong prior-year quarter and margin pressures indicated by variable investment income falling short of expectations. The mixed results and cautious tone on growth moderated enthusiasm.

Key Takeaways

• Japan sales declined 5.6% year-over-year in Q2 due to a tough comparison from the Miraito cancer insurance launch in 2025, though H1 sales remained up 7%.
• Aflac U.S. posted a 2.6% increase in year-over-year sales, supported by growth in group voluntary products and dental & vision lines.
• Variable investment income was $72 million below long-term return expectations, pressuring underlying margins and offsetting some operational gains.
• Japan’s benefit ratio improved by 250 basis points to 64%, reflecting lower benefit payouts but overall net earned premiums declined 3.7%.
• Capital return remained strong with $1.3 billion distributed to shareholders in Q2 through dividends and buybacks, supporting steady capital deployment despite mixed operational signals.